BETHESDA, Maryland, Dec. 22 -- Cystic Fibrosis Foundation issued the following news release: * * * A new CFTR modulator treatment called Alyftrek has been approved for people with CF ages 6 and older who have CFTR mutations that are eligible for Trikafta, as well as 31 other rare mutations that have not been approved previously for any other CFTR modulator. * * * The U.S. Food and Drug Administration (FDA) has approved the new triple-combination modulator Alyftrek (vanzacaftor/tezacaftor/deu more PR